Owkin · Company profile
Owkin · 法国/美国 · AI, models, and data
Registered focus: 多模态生物医学AI、联邦学习、药物发现. Focus is directory metadata; inspect the sources and project evidence below to assess specific capabilities.
Public reviewed developments
Owkin 与赛诺菲合作开发药物研发 AI 智能体
Fri Jun 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据 Owkin 官方公告，与赛诺菲开展多年合作，共同开发生物医药 AI 智能体，安排包含五年许可。该信息属于商业研发安排。
Owkin 与阿斯利康签订三年 K Pro 许可安排
Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据 Owkin 官方公告，与阿斯利康达成安排，基于三年 K Pro 许可开发生物医药 AI 智能体。不是已验证的临床效果。
Collaboration, licensing, and acquisition timeline
Owkin 与赛诺菲合作开发药物研发 AI 智能体
Fri Jun 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据 Owkin 官方公告，与赛诺菲开展多年合作，共同开发生物医药 AI 智能体，安排包含五年许可。该信息属于商业研发安排。
Owkin 与阿斯利康签订三年 K Pro 许可安排
Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据 Owkin 官方公告，与阿斯利康达成安排，基于三年 K Pro 许可开发生物医药 AI 智能体。不是已验证的临床效果。
These are drawn from the latest 2 reviewed developments. A collaboration, model performance, experimental results, and clinical progress each require their own evidence.
Public source records
Estonia and Owkin Partner to Advance Sovereign AI in Biology
Owkin official newsroom · Indexed industry source record · Source published: Tue Sep 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:00 GMT+0000 (Coordinated Universal Time)
Tallinn / Paris, 29 September 2026 – Estonia, led by the National Applied Research Center Metrosert, and Owkin today announced a collaboration to advance sovereign AI in biological and health research, working with Metro
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
Owkin official newsroom · Indexed industry source record · Source published: Fri Sep 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:48 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - September 11, 2026 — Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin official newsroom · Indexed industry source record · Source published: Wed Sep 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:56 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together
Owkin and CRO Aviano Sign Master Partnership Agreement to Foster Collaborative Oncology Research
Owkin official newsroom · Indexed industry source record · Source published: Fri Aug 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:09:15 GMT+0000 (Coordinated Universal Time)
PARIS & PORDENONE, Italy — Owkin, the agentic AI company pioneering the first autonomous AI scientist to revolutionize drug discovery and development, and the Centro di Riferimento Oncologico di Aviano (CRO), a leading I
Owkin to Integrate Kognitic's Clinical Trial Data Into K Pro Through New Collaboration
Owkin official newsroom · Indexed industry source record · Source published: Thu Aug 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:09:24 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company pioneering Biological Artificial SuperIntelligence to revolutionize drug discovery and development, today announced a data collaboration with Kognitic to integrate Kogniti
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Owkin official newsroom · Indexed industry source record · Source published: Fri Jun 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:10 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - 5th June, 2026 - Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to
Owkin and BeOne Medicines Sign Clinical Supply Agreement for Tislelizumab in INVOKE Trial of OKN4395
Owkin official newsroom · Indexed industry source record · Source published: Mon Jun 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:24 GMT+0000 (Coordinated Universal Time)
BeOne Medicines will supply tislelizumab, its PD-1 inhibitor, to Owkin's ongoing INVOKE Phase 1a/1b trial of OKN4395 in patients with advanced solid tumors (NCT06789172). The agreement opens a combination arm pairing OKN
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca
Owkin official newsroom · Indexed industry source record · Source published: Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:37 GMT+0000 (Coordinated Universal Time)
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their t
Verified official and subscription sources
- Owkin official newsroom · Collection enabled · Last successful collection Fri Oct 09 2026 09:08:34 GMT+0000 (Coordinated Universal Time)
Source verification and ongoing collection are shown separately. Indexed source records do not automatically become reviewed events.
Reader guides: from sources to conclusions
Compare models by task and follow collaborations through evidence. Each guide includes original sources and a review date.
How should we compare virtual cells, AI models, and companies?
Compare single-cell models, structure prediction, and protein design by inputs, outputs, tasks, and validation conditions. Distinguish model papers from company capabilities.
Reader guide · updated 2026-10-08
AI drug discovery collaboration timelines: from announcements to evidence
Use real official announcements to distinguish partners, upfront payments, conditional milestones, and R&D progress, and build a traceable collaboration timeline.
Reader guide · updated 2026-10-08
How to read weekly AI drug discovery updates: companies, research, and coverage gaps
Build a weekly reading routine, distinguish announcements, papers, and clinical results, and understand this site’s weekly indexing window, denominators, and source coverage.
Reader guide · updated 2026-10-08